BiotechTube
ENYO Pharma

ENYO Pharma

Lyon, France· Est.
enyopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $108.5M

Overview

ENYO Pharma is a French biotech advancing its lead compound, Vonafexor, a novel FXR agonist, through Phase 2 trials for chronic kidney diseases (CKD) and the rare genetic disorder Alport syndrome. The company leverages a unique drug discovery platform inspired by virus-host protein interactions (virus biomimetism) to develop therapeutics. With a seasoned leadership team and a focused pipeline on significant unmet needs in nephrology and metabolic diseases, ENYO aims to establish Vonafexor as a first-in-class treatment for fibrotic kidney diseases.

NephrologyHepatologyMetabolic Diseases

Technology Platform

Drug discovery platform based on virus biomimetism, inspired by virus-host protein interactions to identify novel therapeutic targets and mechanisms for fibrosis and inflammation.

Funding History

3
Total raised:$108.5M
Series C$60M
Series B$35M
Series A$13.5M

Opportunities

The massive, underserved markets for Chronic Kidney Disease and MASH present multi-billion dollar opportunities.
Positive Phase 2 data in Alport Syndrome provides a catalyst for orphan drug development and potential regulatory advantages.
Demonstrating a favorable renal profile with an FXR agonist could provide a key differentiation in a competitive class.

Risk Factors

High clinical development risk as programs advance to larger, pivotal studies.
Intense competition in the FXR agonist space, particularly in MASH, from companies with greater resources.
Dependence on successful future fundraising to finance costly late-stage trials as a private, pre-revenue company.

Competitive Landscape

In nephrology, ENYO competes with other companies developing therapies for Alport and CKD, but few are targeting FXR. In MASH, the competitive landscape is crowded with numerous late-stage players targeting various pathways (FXR, PPAR, THR-β). ENYO's key differentiator is Vonafexor's claimed beneficial effect on kidney function, a point of concern for some other FXR agonists.

More companies in Small Molecule Drugs →More companies in France →